215% return in 2 years: Buy this pharma stocks before Q1FY25 results - Check target price by Anil Singhvi

Zydus Lifesciences Share Price Target: The result season for the first quarter of the financial year 2024-25 is about to begin. Ahead of that, market wizard Anil Singhvi is of the view that the performance of pharma sector companies is expected to be good. Considering this, there is an opportunity for positional investors to earn money and Singhvi has advised investors to buy shares of Zydus Lifesciences before the company announces its Q1FY25 results. 

Zydus Lifesciences Share Price

The counter ended the session at Rs 1137.20, higher by around 3.89 per cent from the previous close of Rs 1094.65. The counter had touched the intraday high of Rs 1144. The shares of Zydus Lifesciences, which has a market cap of Rs 1,14,428.93 crore, have a 52-week high of Rs 1,171.95 and a 52-week low of Rs 56.05.

Zydus Lifesciences Q1 Results Strong 

Zee Business Managing Editor Anil Singhvi said that Zydus Lifesciences is expected to have strong Q1 results. While the average revenue growth of companies in the pharma sector is expected to be 10 per cent, the revenue growth of Zydus Lifesciences is expected to be just double i.e. 20 per cent. 

Overall, the profit of companies in the pharma sector is expected to grow by 18 per cent. At the same time, the profit growth of Zydus is expected to be 25 per cent. In such a situation, the stock is expected to show action on the basis of strong results and therefore positional investors can take entry.

Zydus Lifesciences gets tentative approval from USFDA for BP-lowering drug 

Zydus Lifesciences on Thursday said it has received tentative approval from the US health regulator to market its generic Azilsartan Medoxomil tablets used to treat high blood pressure.

The tentative approval by the US Food and Drug Administration (USFDA) is for Azilsartan Medoxomil tablets of strengths 40 mg and 80 mg, Zydus Lifesciences said in a regulatory filing.

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, it added.

Zydus Lifesciences Share Price Target

Anil Singhvi has advised investors to buy this pharma stock when it is available in the range of Rs 1,100. Based on the Q1 results, a target of Rs 1,200 to Rs 1,225 can be set. This stock had made a 52-week high of Rs 1172 on May 21. This is also an all-time high for the stock. In the last week, the stock has gained 7.5 per cent.